SECURE PCI: how important can a subgroup analysis be?
- PMID: 30023111
- PMCID: PMC6036050
- DOI: 10.21037/jtd.2018.05.155
SECURE PCI: how important can a subgroup analysis be?
Conflict of interest statement
Conflicts of Interest: M Kerneis has received research grant support from French federation of Cardiology, Institut Servier, consulting fees or honorarium from Bayer and AstraZeneca. CM Gibson has received research grant support from Angel Medical Corporation, Bayer Corp, CSL Behring, Janssen Pharmaceuticals, Johnson & Johnson Corporation, and Portola Pharmaceuticals; and has received modest consulting monies from Amarin Pharma, Amgen, Arena Pharmaceuticals, Bayer Corporation, Boehringer Ingelheim, Boston Clinical Research Institute, Cardiovascular Research Foundation, Chiesi, CSL Behring, Eli Lilly, Gilead Sciences, Inc., Janssen Pharmaceuticals, Johnson & Johnson Corporation, The Medicines Company, Merk & Co, Inc., Novo Nordisk, Pfizer, Pharma Mar, Portola Pharmaceuticals, Sanofi, Somahlution, St. Francis Hospital, Verson Corporation, and Web MD. Another author has no conflicts of interest to declare.
Comment on
-
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.JAMA. 2018 Apr 3;319(13):1331-1340. doi: 10.1001/jama.2018.2444. JAMA. 2018. PMID: 29525821 Free PMC article. Clinical Trial.
References
-
- Dotani MI, Elnicki DM, Jain AC, et al. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000;86:1128-30, A6. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous